Quantitative CT imaging of the spatial and temporal distribution of liposomes in a rabbit tumor model

Molecular Pharmaceutics

Volumn 6, Issue 2, 2009, Pages 571-580

  Zheng, Jinzi ^a,b   Jaffray, David ^a,b   Allen, Christine ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biodistribution; Computed tomography; Drug delivery; Imaging; Liposome; Pharmacokinetics

Indexed keywords

CHOLESTEROL; CONTRAST MEDIUM; DIPALMITOYLPHOSPHATIDYLCHOLINE; GADOTERIDOL; IODINE; IOHEXOL; LIPOSOME; MACROGOL 2000; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; ISOTOPE LABELING; MALE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RABBIT; SARCOMA; SENSITIVITY AND SPECIFICITY;

ANIMALS; CONTRAST MEDIA; DRUG CARRIERS; FEASIBILITY STUDIES; HETEROCYCLIC COMPOUNDS; IODINE RADIOISOTOPES; IOHEXOL; LIPOSOMES; ORGANOMETALLIC COMPOUNDS; RABBITS; SARCOMA, EXPERIMENTAL; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 64649090485     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800234r     Document Type: Article

References (28)

1. Allen, T. M.; Cheng, W. W.; Hare, J. I.; Laginha, K. M. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med. Chem. 2006, 6 (6), 513-523.
2. Gabizon, A.; Tzemach, D.; Mak, L.; Bronstein, M.; Horowitz, A. T. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J. Drug Targeting 2002, 10 (7), 539-548.
3. Cui, J.; Li, C.; Guo, W.; Li, Y.; Wang, C.; Zhang, L.; Hao, Y.; Wang, Y. Direct comparison of two pegylated liposomal doxo-rubicin formulations: is AUC predictive for toxicity and efcacy? J. Controlled Release, 2007, 118(2), 204-215.
4. Ishida, T.; Atobe, K.; Wang, X.; Kiwada, H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin- encapsulation and high-dose first injection. J Controlled Release 2006, 115 (3), 251-258.
5. Lu, Z. R.; Ye, F.; Vaidya, A. Polymer platforms for drug delivery and biomedical imaging. J. Controlled Release 2007,122 (3), 269-277.
6. Koning, G. A.; Krijger, G. C. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med. Chem. 2007, 7 (4), 425-140.
7. Tashjian, J. A.; Dewhirst, M. W.; Needham, D.; Viglianti, B. L. Rationale for and measurement of liposomal drug delivery with hyperthermia using non-invasive imaging techniques. Int. J. Hyperthermia 2008, 24 (1), 79-90.
8. Nasongkla, N.; Bey, E.; Ren, J.; Ai, H.; Khemtong, C.; Guthi, J. S.; Chin, S. F.; Sherry, A. D.; Boothman, D. A.; Gao, J. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 2006, 6 (11), 2427-2430.
9. Mitra, A.; Nan, A.; Line, B. R.; Ghandehari, H. Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr. Pharm. Des. 2006, 12 (36), 4729-4749.
10. Torchilin, V. P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007, 9 (2), E128-147.
11. Hoffman, A. S. The origins and evolution of "controlled" drug delivery systems, J. Controlled Release 2008, E-pub.
12. Greish, K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drue Targeting 2007, 15 (7-8), 457-464.
13. Torchilin, V. P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 2007, 24 (1), 1-16.
14. Iyer, A. K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drue Discovery Today 2006, 11 (17-18), 812-818.
15. Drummond, D. C.; Noble, C. O.; Hayes, M. E.; Park, J. W.; Kirpotin, D. B. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J. Pharm. Sci. 2008, 97 (11), 4696-4740.
16. Vail, D. M.; Amantea, M. A.; Colbern, G. T.; Martin, F. J.; Hilger, R. A.; Working, P. K. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin. Oncol. 2004, 31 (6 Suppl. 13), 16-35.
17. Harrington, K. J.; Mohammadtaghi, S.; Uster, P. S.; Glass, D.; Peters, A. M.; Vile, R. G.; Stewart, J. S. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 2001, 7 (2), 243-254.
18. Goins, B. A.; Phillips, W. T. The use of scintigraphic imaging as a tool in the development of liposome formulations. Prog. Lipid Res. 2001, 40 (1-2), 95-123.
19. Zheng, J.; Perkins, G.; Kirilova, A.; Allen, C.; Jaffray, D. A. Multimodal contrast agent for combined computed tomography and magnetic resonance imaging applications. Invest. Radiol. 2006, 41 (3), 339-348.
20. Zheng, J.; Liu, J.; Dunne, M.; Jaffray, D. A.; Allen, C. In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications. Pharm. Res. 2007, 24 (6), 1193-1201.
21. Charrois, G. J.; Allen, T. M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim. Biophys. Acta 2004, 1663 (1-2), 167-177.
22. Pathak, A. P. Magnetic resonance imaging of tumor physiology. Methods Mol. Med. 2006, 124, 279-297.
23. Brock, K. K.; Dawson, L. A.; Sharpe, M. B.; Moseley, D. J.; Jaffray, D. A. Feasibility of a novel deformable image registration technique to facilitate classification, targeting, and monitoring of tumor and normal tissue. Int. J. Radiat. Oncol. Biol. Phys. 2006, 64 (4), 1245-1254.
24. Hutton, B. F.; Braun, M. Software for image registration: algorithms, accuracy, efficacy. Semin. Nucl. Med. 2003, 33 (3), 180-192.
25. Mukundan, S., Jr.; Ghaghada, K. B.; Badea, C. T.; Kao, C. Y.; Hedlund, L. W.; Provenzale, J. M.; Johnson, G. A.; Chen, E.; Bellamkonda, R. V.; Annapragada, A. A liposomal nanoscale contrast agent for preclinical CT in mice. AJR, Am. J. Roentgenol. 2006, 186 (2), 300-307.
26. Kao, C. Y.; Hoffman, E. A.; Beck, K. C.; Bellamkonda, R. V.; Annapragada, A. V. Long-residence-time nano-scale liposomal iohexol for X-ray-based blood pool imaging. Acad. Radiol. 2003, 10 (5), 475-483.
27. Ford, N. L.; Graham, K. C.; Groom, A. C.; Macdonald, I. C.; Chambers, A. F.; Holdsworth, D. W. Time-course characterization of the computed tomography contrast enhancement of an iodinated blood-pool contrast agent in mice using a volumetric flat-panel equipped computed tomography scanner. Invest. Radiol. 2006, 41 (4), 384-390.
28. Zheng, J.; Hoisak, J. D.; Allen, C.; Jaffray, D. A. Longitudinal vascular imaging using a novel nano-encapsulated CT and MR contrast agent. Proc. SPIE 2007, 6511, 65111D.